Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy. — Reports highlight new Alzheimer's disease treatments using anti-amyloid-β immunotherapy, but we see major concerns. The trials supporting lecanemab and donanemab approvals have methodological flaws, and the benefits may be smaller than the...

Evidence span

Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy. — Reports highlight new Alzheimer's disease treatments using anti-amyloid-β immunotherapy, but we see major concerns. The trials supporting lecanemab and donanemab approvals have methodological flaws, and the benefits may be smaller than the...

From Høilund-Carlsen PF et al. 2026, Journal of Alzheimer's disease : JAD

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Immunotherapy; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized — Journal of Alzheimer's disease : JAD 2026

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required